What is Kewaunee Scientific's operating income?

Kewaunee Scientific's total operating income in 2026 was $16.72 million, based on the following breakdown: Total Gross Profit: $80.44 million Total Operating Expenses: $63.73 million

Kewaunee Scientific (KEQU) Financials

$35.70 -0.61 (-1.68%)

Closing price 07/9/2026 04:00 PM Eastern

Extended Trading

$35.75 +0.05 (+0.14%)

As of 07/9/2026 04:10 PM Eastern

Compare

Annual Income Statements for Kewaunee Scientific

This table shows Kewaunee Scientific's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026
Period end date	4/30/2016	4/30/2017	4/30/2018	4/30/2019	4/30/2020	4/30/2021	4/30/2022	4/30/2023	4/30/2024	4/30/2025	4/30/2026
Net Income / (Loss) Attributable to Common Shareholders	3.80	4.52	5.28	1.53	-4.69	-3.67	-6.13	0.74	19	11	9.62
Consolidated Net Income / (Loss)	3.88	4.62	5.46	1.69	-4.62	-3.61	-6.00	1.36	19	12	10
Net Income / (Loss) Continuing Operations	3.88	4.62	5.46	1.69	-4.62	-3.61	-6.00	1.36	19	12	10
Total Pre-Tax Income	5.74	6.75	9.62	2.13	-2.87	-2.62	-2.49	4.50	13	15	14
Total Operating Income	5.70	6.54	9.92	2.11	-2.35	-1.32	-2.61	5.36	18	18	17
Total Gross Profit	24	27	32	25	23	24	24	36	52	69	80
Total Revenue	129	139	158	147	148	147	169	219	204	240	282
Operating Revenue	129	139	158	147	148	147	169	219	204	240	282
Total Cost of Revenue	105	112	126	121	124	123	145	184	152	172	202
Operating Cost of Revenue	105	112	126	121	124	123	145	184	152	172	202
Total Operating Expenses	18	20	22	23	26	25	27	30	34	51	64
Other Operating Expenses / (Income)	18	20	22	23	26	25	27	30	34	51	64
Total Other Income / (Expense), net	0.04	0.20	-0.30	0.02	-0.52	-1.30	0.12	-0.87	-5.16	-2.97	-2.98
Interest Expense	0.31	0.29	0.30	0.37	0.49	0.39	0.63	1.81	1.80	3.21	3.86
Other Income / (Expense), net	0.35	0.50	-0.00	0.39	-0.03	-0.91	0.76	0.94	-3.36	0.24	0.88
Income Tax Expense	1.86	2.13	4.16	0.45	1.76	0.99	3.52	3.14	-5.94	3.20	3.27
Net Income / (Loss) Attributable to Noncontrolling Interest	0.08	0.11	0.18	0.16	0.06	0.07	0.12	0.62	0.30	0.18	0.85
Basic Earnings per Share	$1.43	$1.67	$1.94	$0.56	($1.70)	($1.33)	($2.20)	$0.26	$6.51	$3.98	$3.36
Weighted Average Basic Shares Outstanding	2.67M	2.71M	2.72M	2.74M	2.75M	2.76M	2.79M	2.82M	2.88M	2.86M	2.86M
Diluted Earnings per Share	$1.42	$1.66	$1.90	$0.55	($1.70)	($1.33)	($2.20)	$0.25	$6.38	$3.83	$3.22
Weighted Average Diluted Shares Outstanding	2.69M	2.73M	2.78M	2.79M	2.75M	2.76M	2.79M	2.90M	2.94M	2.98M	2.98M
Weighted Average Basic & Diluted Shares Outstanding	2.70M	2.71M	2.74M	2.75M	2.76M	2.77M	2.79M	2.88M	2.84M	2.84M	2.87M

This table shows Kewaunee Scientific's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026	Q4 2026
Period end date	10/31/2023	1/31/2024	4/30/2024	7/31/2024	10/31/2024	1/31/2025	4/30/2025	7/31/2025	10/31/2025	1/31/2026	4/30/2026
Net Income / (Loss) Attributable to Common Shareholders	2.73	2.52	11	2.19	3.01	1.35	4.85	3.09	2.45	0.69	3.39
Consolidated Net Income / (Loss)	2.83	2.53	11	2.24	3.02	1.38	4.95	3.16	2.54	1.08	3.69
Net Income / (Loss) Continuing Operations	2.83	2.53	11	2.24	3.02	1.38	4.95	3.16	2.54	1.08	3.69
Total Pre-Tax Income	4.85	3.52	1.35	2.43	3.93	1.28	7.15	3.92	3.45	1.60	4.76
Total Operating Income	5.11	3.81	5.56	2.58	4.43	2.25	8.50	4.81	4.11	2.58	5.22
Total Gross Profit	13	12	15	12	14	18	24	21	20	19	21
Total Revenue	50	47	57	48	48	67	77	71	70	69	71
Operating Revenue	50	47	57	48	48	67	77	71	70	69	71
Total Cost of Revenue	37	35	42	36	34	49	53	50	50	51	50
Operating Cost of Revenue	37	35	42	36	34	49	53	50	50	51	50
Total Operating Expenses	8.36	8.22	9.08	9.91	9.52	16	16	16	16	16	16
Other Operating Expenses / (Income)	8.36	8.22	9.08	9.91	9.52	16	16	16	16	16	16
Total Other Income / (Expense), net	-0.26	-0.29	-4.21	-0.15	-0.50	-0.98	-1.35	-0.89	-0.65	-0.98	-0.46
Interest Expense	0.37	0.41	0.55	0.47	0.44	1.14	1.16	1.06	1.06	1.11	0.63
Other Income / (Expense), net	0.11	0.12	-3.67	0.33	-0.06	0.16	-0.19	0.17	0.41	0.13	0.17
Income Tax Expense	2.02	0.98	-9.83	0.19	0.92	-0.11	2.20	0.76	0.92	0.53	1.06
Net Income / (Loss) Attributable to Noncontrolling Interest	0.10	0.01	0.15	0.05	0.01	0.03	0.10	0.07	0.09	0.38	0.30
Basic Earnings per Share	$0.94	$0.87	$3.83	$0.77	$1.05	$0.47	$1.69	$1.08	$0.85	$0.24	$1.19
Weighted Average Basic Shares Outstanding	2.90M	2.89M	2.88M	2.85M	2.87M	2.87M	2.86M	2.85M	2.87M	2.87M	2.86M
Diluted Earnings per Share	$0.93	$0.85	$3.74	$0.74	$1.01	$0.45	$1.63	$1.04	$0.82	$0.23	$1.13
Weighted Average Diluted Shares Outstanding	2.93M	2.97M	2.94M	2.97M	2.97M	3.00M	2.98M	2.96M	2.99M	2.98M	2.98M
Weighted Average Basic & Diluted Shares Outstanding	2.90M	2.88M	2.84M	2.87M	2.87M	2.85M	2.84M	2.87M	2.87M	2.87M	2.87M

This table details how cash moves in and out of Kewaunee Scientific's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026
Period end date	4/30/2016	4/30/2017	4/30/2018	4/30/2019	4/30/2020	4/30/2021	4/30/2022	4/30/2023	4/30/2024	4/30/2025	4/30/2026
Net Change in Cash & Equivalents	2.18	7.28	-2.98	0.61	-5.94	0.52	1.16	6.92	12	-8.77	-5.55
Net Cash From Operating Activities	7.27	12	3.18	2.49	4.16	0.91	-7.89	-3.79	20	15	19
Net Cash From Continuing Operating Activities	7.27	12	3.18	2.49	4.16	0.91	-7.89	-3.79	20	15	19
Net Income / (Loss) Continuing Operations	3.88	4.62	5.46	1.69	-4.62	-3.61	-6.00	1.36	19	12	10
Consolidated Net Income / (Loss)	3.88	4.62	5.46	1.69	-4.62	-3.61	-6.00	1.36	19	12	10
Depreciation Expense	2.59	2.70	2.76	2.57	2.65	2.69	2.77	2.87	3.13	4.76	6.28
Amortization Expense	-	-	-	-	-	-	-	-	0.00	0.22	0.57
Non-Cash Adjustments To Reconcile Net Income	0.27	0.24	0.70	0.26	0.62	0.69	0.82	1.01	1.30	2.44	1.53
Changes in Operating Assets and Liabilities, net	0.54	4.10	-5.74	-2.03	5.52	1.15	-5.47	-9.02	-3.92	-4.22	-0.21
Net Cash From Investing Activities	-1.48	-2.48	-3.40	-4.21	-2.47	-2.40	-1.91	-4.15	-4.37	-31	-3.94
Net Cash From Continuing Investing Activities	-1.48	-2.48	-3.40	-4.21	-2.47	-2.40	-1.91	-4.15	-4.37	-31	-3.94
Purchase of Property, Plant & Equipment	-2.19	-2.61	-3.40	-4.21	-2.47	-2.40	-1.91	-4.15	-4.37	-2.17	-3.94
Acquisitions	-	-	-	-	-	-	-	-	0.00	-29	0.00
Net Cash From Financing Activities	-3.40	-2.08	-2.48	2.33	-7.46	1.98	11	15	-3.01	7.41	-19
Net Cash From Continuing Financing Activities	-3.40	-2.08	-2.48	2.33	-7.46	1.98	11	15	-3.01	7.41	-19
Repayment of Debt	-50	-52	-60	-58	-65	-60	-65	-59	-149	-78	-44
Repurchase of Common Equity	-	-	-	-	-	-	-	0.00	-2.00	-1.60	0.00
Payment of Dividends	-2.32	-1.63	-1.87	-2.08	-1.37	-0.11	-	-	0.00	-0.26	-0.34
Issuance of Debt	49	51	59	63	59	62	60	61	148	88	26
Other Financing Activities, net	0.48	0.19	0.01	-0.04	-0.01	0.00	16	14	-0.53	-0.87	-1.41
Other Net Changes in Cash	-	-	-0.29	-	-	-	-	-	-	-0.07	-0.92
Cash Interest Paid	0.31	0.29	0.30	0.35	0.51	0.07	0.48	1.86	1.80	3.37	3.33
Cash Income Taxes Paid	2.39	2.62	2.87	2.46	0.19	-1.80	1.01	3.16	6.24	3.97	3.56

This table details how cash moves in and out of Kewaunee Scientific's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026	Q4 2026
Period end date	10/31/2023	1/31/2024	4/30/2024	7/31/2024	10/31/2024	1/31/2025	4/30/2025	7/31/2025	10/31/2025	1/31/2026	4/30/2026
Net Change in Cash & Equivalents	0.14	5.40	-1.17	-0.75	4.48	-17	4.83	3.28	-6.76	-3.33	1.27
Net Cash From Operating Activities	0.75	9.50	1.15	-0.79	8.44	-2.27	9.41	5.79	-4.27	12	5.46
Net Cash From Continuing Operating Activities	0.75	9.50	1.15	-0.79	8.44	-2.27	9.41	5.79	-4.27	12	5.46
Net Income / (Loss) Continuing Operations	2.83	2.53	11	2.24	3.02	1.38	4.95	3.16	2.54	1.08	3.69
Consolidated Net Income / (Loss)	2.83	2.53	11	2.24	3.02	1.38	4.95	3.16	2.54	1.08	3.69
Depreciation Expense	0.77	0.82	0.82	0.82	0.81	1.56	1.58	1.55	1.58	1.60	1.56
Amortization Expense	-	-	-	0.00	-	-	0.22	0.09	0.09	0.32	0.06
Non-Cash Adjustments To Reconcile Net Income	0.30	0.28	0.41	0.33	0.39	0.94	0.79	0.99	-0.87	0.62	0.80
Changes in Operating Assets and Liabilities, net	-3.15	5.87	-11	-4.18	4.23	-6.15	1.88	0.00	-7.61	8.03	-0.64
Net Cash From Investing Activities	-1.27	-0.48	-0.98	-0.28	-0.68	-29	-0.52	-0.77	-1.57	-0.67	-0.93
Net Cash From Continuing Investing Activities	-1.27	-0.48	-0.98	-0.28	-0.68	-29	-0.52	-0.77	-1.57	-0.67	-0.93
Purchase of Property, Plant & Equipment	-1.27	-0.48	-0.98	-0.28	-0.68	-0.69	-0.52	-0.77	-1.57	-0.67	-0.93
Net Cash From Financing Activities	0.78	-3.63	-1.47	0.34	-3.23	15	-4.34	-1.46	-0.85	-14	-2.95
Net Cash From Continuing Financing Activities	0.78	-3.63	-1.47	0.34	-3.23	15	-4.34	-1.46	-0.85	-14	-2.95
Repayment of Debt	-38	-36	-36	-38	-29	-8.17	-3.68	-2.62	-2.11	-35	-4.34
Issuance of Debt	39	33	36	38	26	23	1.29	1.38	1.98	21	1.62
Other Financing Activities, net	0.04	-0.24	-0.18	-0.19	-0.18	-0.27	-0.25	-0.22	-0.73	-0.23	-0.23
Other Net Changes in Cash	-	-	-	-0.02	-0.05	-0.27	0.28	-0.28	-0.07	-0.25	-0.31
Cash Interest Paid	-	-	0.55	0.47	-	-	1.84	0.52	1.42	0.81	0.59

This table presents Kewaunee Scientific's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026
Period end date	4/30/2016	4/30/2017	4/30/2018	4/30/2019	4/30/2020	4/30/2021	4/30/2022	4/30/2023	4/30/2024	4/30/2025	4/30/2026
Total Assets	72	81	85	87	84	89	119	119	135	195	178
Total Current Assets	51	60	64	65	54	60	92	88	97	118	105
Cash & Equivalents	5.22	13	9.72	11	4.37	5.21	4.43	8.08	23	15	9.95
Restricted Cash	1.57	1.44	1.24	0.51	0.85	0.53	2.46	5.74	2.67	2.22	1.67
Accounts Receivable	28	30	33	33	28	33	41	46	45	62	59
Inventories, net	16	15	19	17	15	17	24	22	21	33	31
Prepaid Expenses	0.71	1.05	2.22	3.74	2.91	4.37	6.16	6.14	5.14	5.97	4.51
Plant, Property, & Equipment, net	14	14	15	16	16	16	15	16	18	23	22
Total Noncurrent Assets	7.33	7.08	6.03	5.40	13	13	12	15	20	53	51
Goodwill	-	-	-	-	-	-	-	-	0.00	12	12
Intangible Assets	-	-	-	-	-	-	-	-	0.00	18	16
Noncurrent Deferred & Refundable Income Taxes	3.39	3.16	1.87	1.83	0.34	-	-	0.00	7.40	3.99	3.83
Other Noncurrent Operating Assets	3.94	3.92	4.16	3.58	13	13	12	15	13	19	18
Total Liabilities & Shareholders' Equity	72	81	85	87	84	89	119	119	135	195	178
Total Liabilities	34	38	37	40	45	48	83	80	79	128	101
Total Current Liabilities	21	27	28	33	27	34	42	40	41	54	48
Short-Term Debt	4.24	4.51	5.05	11	4.72	6.83	1.59	3.59	3.10	3.89	4.97
Accounts Payable	12	12	15	15	13	17	27	24	23	27	22
Accrued Expenses	1.87	1.85	2.12	1.51	1.26	1.36	3.34	1.77	1.06	3.35	3.24
Current Deferred Revenue	0.79	5.81	1.88	1.60	2.51	3.12	3.53	4.10	4.37	6.07	4.15
Current Employee Benefit Liabilities	2.33	2.77	3.81	3.74	4.16	4.73	4.50	4.30	6.04	9.21	8.82
Other Current Liabilities	-	-	-	0.02	1.30	1.37	2.02	2.69	2.95	4.16	4.71
Total Noncurrent Liabilities	13	11	9.28	6.79	18	14	40	40	38	75	53
Long-Term Debt	3.35	2.43	1.26	0.10	-	-	-	-	0.00	34	15
Capital Lease Obligations	-	-	-	-	-	0.09	0.23	0.15	0.24	0.15	0.28
Noncurrent Deferred & Payable Income Tax Liabilities	-	-	-	0.00	0.40	0.31	0.43	0.94	1.22	1.10	0.91
Noncurrent Employee Benefit Liabilities	-	-	-	5.88	-	4.65	4.16	3.55	3.01	3.71	4.81
Other Noncurrent Operating Liabilities	9.55	8.30	8.01	0.81	18	8.67	35	36	33	36	32
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	39	43	48	48	39	41	36	38	56	66	77
Total Preferred & Common Equity	38	43	48	47	38	41	36	37	55	64	75
Total Common Equity	38	43	48	47	38	41	36	37	55	64	75
Common Stock	9.10	9.48	9.85	10	10	11	11	12	13	13	14
Retained Earnings	37	40	44	44	38	34	28	29	48	59	69
Treasury Stock	-0.05	-0.05	-0.05	-0.05	-0.05	-0.05	-0.05	-0.05	-2.05	-3.65	-3.65
Accumulated Other Comprehensive Income / (Loss)	-7.63	-6.32	-5.90	-6.41	-9.60	-3.58	-3.74	-3.44	-3.38	-3.80	-4.61
Noncontrolling Interest	0.31	0.37	0.46	0.60	0.29	0.25	0.49	1.08	1.45	1.79	2.09

This table presents Kewaunee Scientific's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026	Q2 2026	Q3 2026
Period end date	7/31/2023	10/31/2023	1/31/2024	7/31/2024	10/31/2024	1/31/2025	7/31/2025	10/31/2025	1/31/2026
Total Assets	125	122	126	132	134	189	193	189	176
Total Current Assets	94	91	96	93	96	109	117	114	104
Cash & Equivalents	13	14	21	24	26	9.45	19	13	8.15
Restricted Cash	8.87	7.99	5.80	0.98	3.70	2.88	0.95	1.09	2.19
Accounts Receivable	42	43	41	44	42	57	57	59	54
Inventories, net	22	22	22	19	19	32	35	35	33
Prepaid Expenses	7.37	4.90	6.09	4.68	6.23	7.30	4.89	5.45	6.19
Plant, Property, & Equipment, net	17	18	17	17	17	24	23	23	23
Plant, Property & Equipment, gross	63	64	64	64	65	73	73	74	75
Accumulated Depreciation	46	46	47	47	48	49	50	51	52
Total Noncurrent Assets	14	13	13	22	21	57	54	52	50
Goodwill	-	-	-	-	-	14	12	12	12
Intangible Assets	-	-	-	-	-	18	17	17	17
Noncurrent Deferred & Refundable Income Taxes	-	-	-	8.09	8.31	3.88	4.21	3.83	3.57
Other Noncurrent Operating Assets	14	13	13	14	13	20	19	19	17
Total Liabilities & Shareholders' Equity	125	122	126	132	134	189	193	189	176
Total Liabilities	84	78	81	75	74	127	125	117	103
Total Current Liabilities	44	39	42	37	36	50	50	46	49
Short-Term Debt	5.05	5.86	3.18	3.63	0.81	4.13	3.40	4.02	6.44
Accounts Payable	22	19	19	21	21	25	26	23	24
Accrued Expenses	2.41	0.85	1.00	1.53	1.29	2.63	3.95	2.90	3.23
Current Deferred Revenue	7.07	4.92	10	4.94	6.24	7.77	4.98	4.34	4.07
Current Employee Benefit Liabilities	4.90	5.01	5.77	3.10	3.71	6.84	7.80	7.62	7.32
Other Current Liabilities	2.66	2.93	2.86	2.88	2.97	4.27	4.03	4.28	4.10
Total Noncurrent Liabilities	40	40	39	38	37	77	74	72	55
Long-Term Debt	-	-	-	-	-	35	34	32	16
Capital Lease Obligations	0.14	0.26	0.25	0.22	0.16	0.15	0.14	0.32	0.30
Noncurrent Deferred & Payable Income Tax Liabilities	0.99	1.05	1.13	1.27	1.04	1.09	1.16	1.22	0.90
Noncurrent Employee Benefit Liabilities	3.86	3.84	3.66	3.52	3.63	3.82	4.33	4.54	4.60
Other Noncurrent Operating Liabilities	35	34	34	33	33	37	35	34	33
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	41	43	45	58	61	62	69	72	73
Total Preferred & Common Equity	39	42	44	56	59	61	67	70	71
Total Common Equity	39	42	44	56	59	61	67	70	71
Common Stock	12	12	12	12	12	13	13	13	14
Retained Earnings	31	34	36	50	53	54	62	64	65
Accumulated Other Comprehensive Income / (Loss)	-3.59	-3.84	-3.88	-3.50	-3.57	-3.84	-4.21	-4.38	-4.77
Other Equity Adjustments	-0.05	-0.10	-0.84	-2.05	-2.05	-2.05	-3.65	-3.65	-3.65
Noncontrolling Interest	1.11	1.31	1.26	1.49	1.33	1.32	1.79	1.87	1.85

This table displays calculated financial ratios and metrics derived from Kewaunee Scientific's official financial filings.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026
Period end date	4/30/2016	4/30/2017	4/30/2018	4/30/2019	4/30/2020	4/30/2021	4/30/2022	4/30/2023	4/30/2024	4/30/2025	4/30/2026
DEI Shares Outstanding	2,684,580.00	2,711,953.00	2,724,932.00	2,746,598.00	2,750,143.00	2,762,797.00	2,789,873.00	2,830,200.00	2,875,104.00	2,854,464.00	2,866,384.00
DEI Adjusted Shares Outstanding	2,684,580.00	2,711,953.00	2,724,932.00	2,746,598.00	2,750,143.00	2,762,797.00	2,789,873.00	2,830,200.00	2,875,104.00	2,854,464.00	2,866,384.00
DEI Earnings Per Adjusted Shares Outstanding	1.42	1.66	1.94	0.56	-1.70	-1.33	-2.20	0.26	6.52	4.00	3.36
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	8.25%	7.72%	14.07%	-7.28%	0.68%	-0.05%	14.51%	29.98%	-7.17%	18.02%	17.27%
EBITDA Growth	3.75%	12.77%	30.17%	-60.00%	-94.46%	63.35%	99.56%	901.09%	96.76%	27.34%	6.38%
EBIT Growth	5.87%	16.43%	40.92%	-74.78%	-194.88%	6.11%	16.83%	440.15%	136.68%	20.65%	-2.24%
NOPAT Growth	8.97%	16.39%	25.62%	-70.32%	-198.26%	43.88%	-98.18%	188.77%	1,538.57%	-47.61%	-8.45%
Net Income Growth	6.51%	19.16%	18.14%	-69.07%	-373.93%	21.99%	-66.43%	122.64%	1,302.28%	-39.22%	-9.65%
EPS Growth	6.77%	16.90%	14.46%	-71.05%	-409.09%	21.76%	-65.41%	111.36%	2,452.00%	-39.97%	-15.93%
Operating Cash Flow Growth	217.37%	60.39%	-72.71%	-21.77%	67.11%	-78.08%	-964.58%	51.93%	616.20%	-24.44%	26.04%
Free Cash Flow Firm Growth	2,977.54%	114.94%	-121.99%	-26.27%	455.40%	-172.09%	280.87%	-55.70%	394.61%	-285.20%	136.81%
Invested Capital Growth	0.83%	-7.87%	20.12%	8.67%	-19.27%	11.69%	-27.12%	-8.67%	18.31%	159.09%	-2.09%
Revenue Q/Q Growth	3.05%	0.35%	6.70%	-6.24%	-0.33%	3.11%	6.97%	1.98%	1.35%	9.29%	-2.00%
EBITDA Q/Q Growth	13.20%	-1.62%	5.39%	-44.47%	291.16%	-21.27%	132.48%	4.51%	-4.96%	47.44%	-11.27%
EBIT Q/Q Growth	19.35%	-2.22%	7.99%	-61.93%	13.30%	-3.68%	66.88%	5.84%	-6.50%	55.45%	-14.25%
NOPAT Q/Q Growth	24.95%	-0.68%	10.84%	-64.78%	14.48%	21.34%	52.60%	2,471.55%	170.46%	-52.65%	-12.37%
Net Income Q/Q Growth	23.00%	0.79%	2.98%	-61.96%	2.92%	-107.78%	30.23%	2,257.14%	112.41%	-34.98%	-10.71%
EPS Q/Q Growth	23.48%	0.61%	1.60%	-64.29%	3.95%	-107.81%	29.71%	200.00%	112.67%	-35.52%	-13.44%
Operating Cash Flow Q/Q Growth	897.26%	16.78%	-38.39%	-70.22%	62.10%	-65.68%	-140.25%	63.36%	7.64%	126.70%	-17.48%
Free Cash Flow Firm Q/Q Growth	224.35%	18.25%	-226.89%	-177.78%	249.39%	-274.98%	238.51%	-72.91%	78.13%	-4.12%	-21.82%
Invested Capital Q/Q Growth	-4.15%	-7.41%	1.46%	5.25%	-6.59%	16.43%	-21.93%	19.19%	55.14%	-2.20%	0.36%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	18.43%	19.20%	20.35%	17.28%	15.88%	16.27%	14.34%	16.21%	25.55%	28.63%	28.52%
EBITDA Margin	6.71%	7.03%	8.02%	3.46%	0.19%	0.31%	0.54%	4.18%	8.86%	9.55%	8.67%
Operating Margin	4.43%	4.72%	6.28%	1.44%	-1.59%	-0.89%	-1.54%	2.44%	8.97%	7.39%	5.93%
EBIT Margin	4.70%	5.08%	6.28%	1.71%	-1.61%	-1.51%	-1.10%	2.87%	7.32%	7.48%	6.24%
Profit (Net Income) Margin	3.01%	3.33%	3.45%	1.15%	-3.13%	-2.45%	-3.55%	0.62%	9.35%	4.82%	3.71%
Tax Burden Percent	67.56%	68.49%	56.74%	79.10%	161.34%	137.83%	241.57%	30.21%	145.26%	78.34%	76.20%
Interest Burden Percent	94.94%	95.85%	96.99%	85.33%	120.78%	117.46%	134.11%	71.36%	87.94%	82.14%	78.05%
Effective Tax Rate	32.44%	31.52%	43.26%	20.90%	0.00%	0.00%	0.00%	69.79%	-45.26%	21.66%	23.80%
Return on Invested Capital (ROIC)	9.82%	11.85%	14.10%	3.68%	-3.84%	-2.28%	-4.95%	5.45%	85.65%	23.06%	14.78%
ROIC Less NNEP Spread (ROIC-NNEP)	11.02%	7.35%	17.03%	2.98%	677.88%	-778.52%	209.83%	8.90%	131.53%	284.70%	-0.75%
Return on Net Nonoperating Assets (RNNOA)	0.69%	-0.56%	-2.17%	-0.16%	-6.86%	-6.72%	-10.51%	-1.81%	-45.40%	-4.14%	-0.15%
Return on Equity (ROE)	10.51%	11.29%	11.94%	3.52%	-10.70%	-9.00%	-15.46%	3.64%	40.25%	18.92%	14.63%
Cash Return on Invested Capital (CROIC)	8.99%	20.04%	-4.17%	-4.63%	17.48%	-13.33%	26.42%	14.51%	68.88%	-65.55%	16.90%
Operating Return on Assets (OROA)	8.52%	9.18%	11.95%	2.90%	-2.77%	-2.57%	-1.78%	5.30%	11.76%	10.93%	9.44%
Return on Assets (ROA)	5.46%	6.03%	6.58%	1.96%	-5.40%	-4.16%	-5.77%	1.14%	15.03%	7.03%	5.61%
Return on Common Equity (ROCE)	10.42%	11.20%	11.83%	3.48%	-10.59%	-8.94%	-15.31%	3.56%	39.18%	18.42%	14.23%
Return on Equity Simple (ROE_SIMPLE)	10.14%	10.77%	11.44%	3.58%	-12.04%	-8.75%	-16.82%	3.63%	34.80%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	3.85	4.48	5.63	1.67	-1.64	-0.92	-1.83	1.62	27	14	13
NOPAT Margin	2.99%	3.23%	3.56%	1.14%	-1.11%	-0.62%	-1.08%	0.74%	13.03%	5.79%	4.52%
Net Nonoperating Expense Percent (NNEP)	-1.20%	4.51%	-2.92%	0.69%	-681.71%	776.24%	-214.78%	-3.45%	-45.88%	-261.64%	15.53%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	44.60%	13.35%	13.15%
Cost of Revenue to Revenue	81.57%	80.80%	79.65%	82.72%	84.12%	83.73%	85.66%	83.79%	74.45%	71.37%	71.48%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	14.00%	14.48%	14.07%	15.84%	17.47%	17.16%	15.89%	13.77%	16.57%	21.25%	22.60%
Earnings before Interest and Taxes (EBIT)	6.05	7.04	9.92	2.50	-2.37	-2.23	-1.85	6.30	15	18	18
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	8.64	9.74	13	5.07	0.28	0.46	0.92	9.17	18	23	24
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.06	1.35	1.90	1.29	0.73	0.80	1.11	1.23	1.87	1.40	1.42
Price to Tangible Book Value (P/TBV)	1.06	1.35	1.90	1.29	0.73	0.80	1.11	1.23	1.87	2.65	2.31
Price to Revenue (P/Rev)	0.32	0.42	0.57	0.42	0.19	0.22	0.24	0.21	0.50	0.38	0.38
Price to Earnings (P/E)	10.70	12.80	17.20	39.80	0.00	0.00	0.00	62.32	5.47	7.93	11.03
Dividend Yield	3.37%	2.72%	1.98%	3.34%	7.43%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	9.35%	7.82%	5.82%	2.51%	0.00%	0.00%	0.00%	1.60%	18.27%	12.62%	9.07%
Enterprise Value to Invested Capital (EV/IC)	1.06	1.41	1.99	1.29	0.73	0.81	1.13	1.30	2.42	1.30	1.37
Enterprise Value to Revenue (EV/Rev)	0.32	0.37	0.55	0.42	0.19	0.23	0.21	0.17	0.40	0.47	0.41
Enterprise Value to EBITDA (EV/EBITDA)	4.84	5.25	6.83	12.04	99.38	75.35	38.42	4.03	4.52	4.92	4.77
Enterprise Value to EBIT (EV/EBIT)	6.91	7.27	8.73	24.42	0.00	0.00	0.00	5.87	5.46	6.28	6.63
Enterprise Value to NOPAT (EV/NOPAT)	10.86	11.42	15.39	36.56	0.00	0.00	0.00	22.82	3.07	8.12	9.16
Enterprise Value to Operating Cash Flow (EV/OCF)	5.75	4.39	27.22	24.53	6.71	37.93	0.00	0.00	4.17	7.64	6.26
Enterprise Value to Free Cash Flow (EV/FCFF)	11.86	6.75	0.00	0.00	3.74	0.00	3.61	8.57	3.82	0.00	8.01
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.20	0.16	0.13	0.23	0.12	0.17	0.05	0.10	0.06	0.57	0.26
Long-Term Debt to Equity	0.09	0.06	0.03	0.00	0.00	0.00	0.01	0.00	0.00	0.51	0.20
Financial Leverage	0.06	-0.08	-0.13	-0.05	-0.01	0.01	-0.05	-0.20	-0.35	-0.01	0.20
Leverage Ratio	1.92	1.87	1.82	1.80	1.98	2.16	2.68	3.18	2.68	2.69	2.61
Compound Leverage Factor	1.83	1.80	1.76	1.53	2.39	2.54	3.59	2.27	2.36	2.21	2.03
Debt to Total Capital	16.45%	13.83%	11.59%	18.43%	10.87%	14.29%	4.78%	8.85%	5.60%	36.44%	20.70%
Short-Term Debt to Total Capital	9.19%	8.98%	9.27%	18.26%	10.87%	14.11%	4.18%	8.50%	5.20%	3.73%	5.13%
Long-Term Debt to Total Capital	7.26%	4.84%	2.32%	0.17%	0.00%	0.19%	0.60%	0.35%	0.39%	32.71%	15.57%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.67%	0.75%	0.85%	1.03%	0.66%	0.51%	1.28%	2.55%	2.43%	1.72%	2.16%
Common Equity to Total Capital	82.88%	85.43%	87.57%	80.54%	88.47%	85.20%	93.94%	88.60%	91.97%	61.84%	77.14%
Debt to EBITDA	0.88	0.71	0.50	2.12	16.79	15.07	1.98	0.41	0.18	1.65	0.82
Net Debt to EBITDA	0.09	-0.72	-0.37	-0.07	-1.77	2.59	-5.54	-1.10	-1.25	0.91	0.35
Long-Term Debt to EBITDA	0.39	0.25	0.10	0.02	0.00	0.20	0.25	0.02	0.01	1.48	0.62
Debt to NOPAT	1.97	1.55	1.12	6.45	-2.87	-7.51	-0.99	2.30	0.13	2.73	1.57
Net Debt to NOPAT	0.21	-1.56	-0.82	-0.23	0.30	-1.29	2.78	-6.22	-0.85	1.50	0.66
Long-Term Debt to NOPAT	0.87	0.54	0.22	0.06	0.00	-0.10	-0.12	0.09	0.01	2.45	1.18
Altman Z-Score	3.98	4.10	4.96	3.85	3.06	2.87	2.49	3.19	3.65	2.79	3.46
Noncontrolling Interest Sharing Ratio	0.86%	0.84%	0.91%	1.11%	1.03%	0.67%	0.94%	2.09%	2.67%	2.64%	2.71%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.43	2.22	2.33	2.00	2.00	1.77	2.17	2.20	2.37	2.20	2.18
Quick Ratio	1.58	1.57	1.53	1.34	1.20	1.11	1.40	1.35	1.68	1.44	1.42
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	3.52	7.58	-1.67	-2.10	7.48	-5.39	9.75	4.32	21	-40	15
Operating Cash Flow to CapEx	332.46%	446.65%	93.76%	59.10%	168.80%	38.05%	-413.26%	-91.37%	447.38%	682.50%	473.28%
Free Cash Flow to Firm to Interest Expense	11.52	25.94	-5.57	-5.73	15.16	-13.85	15.42	2.39	11.87	-12.31	3.77
Operating Cash Flow to Interest Expense	23.76	39.94	10.65	6.78	8.44	2.34	-12.48	-2.10	10.87	4.60	4.82
Operating Cash Flow Less CapEx to Interest Expense	16.61	31.00	-0.71	-4.69	3.44	-3.82	-15.50	-4.40	8.44	3.93	3.81
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.81	1.81	1.90	1.70	1.72	1.70	1.62	1.85	1.61	1.46	1.51
Accounts Receivable Turnover	4.52	4.80	5.05	4.45	4.81	4.84	4.56	5.03	4.47	4.48	4.66
Inventory Turnover	7.40	7.33	7.52	6.78	7.63	7.75	7.18	8.05	7.13	6.41	6.36
Fixed Asset Turnover	8.98	9.85	11.02	9.42	9.01	9.14	10.86	13.93	11.97	11.78	12.38
Accounts Payable Turnover	9.14	9.44	9.41	8.10	8.77	8.26	6.56	7.22	6.47	6.82	8.15
Days Sales Outstanding (DSO)	80.79	76.03	72.23	82.09	75.85	75.42	80.12	72.62	81.64	81.54	78.39
Days Inventory Outstanding (DIO)	49.35	49.82	48.54	53.83	47.84	47.07	50.86	45.34	51.21	56.92	57.39
Days Payable Outstanding (DPO)	39.93	38.66	38.78	45.08	41.62	44.18	55.63	50.53	56.37	53.49	44.81
Cash Conversion Cycle (CCC)	90.21	87.19	81.99	90.84	82.07	78.31	75.35	67.43	76.47	84.98	90.97
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	39	36	44	47	38	43	31	28	34	87	85
Invested Capital Turnover	3.28	3.67	3.96	3.23	3.45	3.65	4.58	7.38	6.57	3.99	3.27
Increase / (Decrease) in Invested Capital	0.33	-3.10	7.29	3.77	-9.12	4.47	-12	-2.70	5.20	53	-1.82
Enterprise Value (EV)	42	51	87	61	28	35	35	37	81	113	117
Market Capitalization	41	58	91	61	28	33	40	46	103	90	106
Book Value per Share	$14.25	$15.81	$17.52	$17.15	$13.97	$14.93	$12.79	$13.22	$19.05	$22.58	$26.07
Tangible Book Value per Share	$14.25	$15.81	$17.52	$17.15	$13.97	$14.93	$12.79	$13.22	$19.05	$11.96	$16.03
Total Capital	46	50	55	58	43	48	38	42	60	104	97
Total Debt	7.59	6.94	6.32	11	4.72	6.92	1.82	3.74	3.33	38	20
Total Long-Term Debt	3.35	2.43	1.26	0.10	0.00	0.09	0.23	0.15	0.24	34	15
Net Debt	0.80	-7.00	-4.64	-0.38	-0.50	1.19	-5.08	-10	-23	21	8.44
Capital Expenditures (CapEx)	2.19	2.61	3.40	4.21	2.47	2.40	1.91	4.15	4.37	2.17	3.94
Debt-free, Cash-free Net Working Capital (DFCFNWC)	27	23	31	32	27	27	44	38	33	51	50
Debt-free Net Working Capital (DFNWC)	34	37	42	43	32	33	51	51	59	69	62
Net Working Capital (NWC)	30	33	37	33	27	26	49	48	56	65	57
Net Nonoperating Expense (NNE)	-0.03	-0.14	0.17	-0.02	2.98	2.69	4.18	0.26	7.50	2.33	2.27
Net Nonoperating Obligations (NNO)	0.80	-7.00	-4.64	-0.38	-0.50	1.19	-5.08	-10	-23	21	8.44
Total Depreciation and Amortization (D&A)	2.59	2.70	2.76	2.57	2.65	2.69	2.77	2.87	3.13	4.98	6.85
Debt-free, Cash-free Net Working Capital to Revenue	21.35%	16.93%	19.53%	21.94%	18.08%	18.56%	26.04%	17.15%	16.29%	21.36%	17.87%
Debt-free Net Working Capital to Revenue	26.62%	26.99%	26.46%	29.55%	21.61%	22.45%	30.12%	23.44%	29.02%	28.50%	21.99%
Net Working Capital to Revenue	23.33%	23.73%	23.27%	22.26%	18.42%	17.82%	29.18%	21.81%	27.50%	26.89%	20.23%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.43	$1.67	$1.91	$0.56	($1.70)	($1.33)	($2.20)	$0.26	$6.51	$3.98	$3.36
Adjusted Weighted Average Basic Shares Outstanding	2.67M	2.71M	2.72M	2.74M	2.75M	2.76M	2.79M	2.82M	2.88M	2.86M	2.86M
Adjusted Diluted Earnings per Share	$1.42	$1.66	$1.87	$0.55	($1.70)	($1.33)	($2.20)	$0.25	$6.38	$3.83	$3.22
Adjusted Weighted Average Diluted Shares Outstanding	2.69M	2.73M	2.78M	2.79M	2.75M	2.76M	2.79M	2.90M	2.94M	2.98M	2.98M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	2.70M	2.71M	2.74M	2.75M	2.76M	2.77M	2.79M	2.88M	2.84M	2.84M	2.87M
Normalized Net Operating Profit after Tax (NOPAT)	3.85	4.48	5.63	1.67	-1.64	-0.92	-1.83	3.75	13	14	13
Normalized NOPAT Margin	2.99%	3.23%	3.56%	1.14%	-1.11%	-0.62%	-1.08%	1.71%	6.28%	5.79%	4.52%
Pre Tax Income Margin	4.46%	4.87%	6.09%	1.46%	-1.94%	-1.77%	-1.47%	2.05%	6.44%	6.15%	4.87%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	19.75	24.10	33.17	6.81	-4.81	-5.73	-2.93	3.49	8.29	5.60	4.56
NOPAT to Interest Expense	12.58	15.34	18.82	4.55	-3.33	-2.37	-2.89	0.90	14.76	4.33	3.30
EBIT Less CapEx to Interest Expense	12.61	15.16	21.82	-4.66	-9.81	-11.89	-5.95	1.19	5.86	4.93	3.54
NOPAT Less CapEx to Interest Expense	5.43	6.40	7.47	-6.93	-8.33	-8.53	-5.91	-1.40	12.33	3.65	2.28
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	59.94%	35.19%	34.23%	123.28%	-29.58%	-2.99%	0.00%	0.00%	0.00%	2.25%	3.24%
Augmented Payout Ratio	59.94%	35.19%	34.23%	123.28%	-29.58%	-2.99%	0.00%	0.00%	10.48%	16.03%	3.24%

This table displays calculated financial ratios and metrics derived from Kewaunee Scientific's official financial filings.

Metric	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026	Q4 2026
Period end date	10/31/2023	1/31/2024	4/30/2024	7/31/2024	10/31/2024	1/31/2025	4/30/2025	7/31/2025	10/31/2025	1/31/2026	4/30/2026
DEI Shares Outstanding	2,904,094.00	2,901,671.00	2,875,104.00	-	-	-	2,854,464.00	2,844,290.00	2,865,694.00	2,866,384.00	2,866,384.00
DEI Adjusted Shares Outstanding	2,904,094.00	2,901,671.00	2,875,104.00	-	-	-	2,854,464.00	2,844,290.00	2,865,694.00	2,866,384.00	2,866,384.00
DEI Earnings Per Adjusted Shares Outstanding	0.94	0.87	3.84	-	-	-	1.70	1.09	0.85	0.24	1.18
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-7.57%	-23.09%	5.03%	-2.90%	-5.30%	43.59%	36.06%	46.93%	46.75%	3.32%	-7.45%
EBITDA Growth	288.26%	47.99%	-25.78%	-19.21%	-13.50%	-16.19%	272.60%	78.13%	19.48%	16.60%	-30.74%
EBIT Growth	525.54%	57.29%	-35.40%	-25.26%	-16.18%	-38.56%	339.32%	71.54%	3.22%	12.60%	-35.19%
NOPAT Growth	1,681.04%	123.34%	3,524.72%	-15.51%	13.96%	-11.02%	-87.25%	63.45%	-11.24%	-29.03%	-31.16%
Net Income Growth	2,582.46%	130.69%	921.85%	-11.01%	6.54%	-45.40%	-55.75%	41.15%	-15.82%	-22.20%	-25.37%
EPS Growth	1,133.33%	240.00%	938.89%	-13.95%	8.60%	-47.06%	-56.42%	40.54%	-18.81%	-48.89%	-30.67%
Operating Cash Flow Growth	117.49%	420.84%	571.19%	-109.72%	1,029.32%	-123.85%	721.57%	829.35%	-150.56%	613.99%	-41.96%
Free Cash Flow Firm Growth	-122.46%	-71.50%	931.02%	-28.66%	87.57%	-1,421.64%	-216.26%	-373.49%	-7,920.05%	108.96%	112.33%
Invested Capital Growth	47.09%	-9.11%	18.31%	49.68%	14.87%	311.02%	159.09%	136.83%	194.23%	-4.59%	-2.09%
Revenue Q/Q Growth	1.20%	-7.25%	21.22%	-14.65%	-1.30%	40.62%	14.86%	-7.83%	-1.42%	-0.99%	2.88%
EBITDA Q/Q Growth	30.12%	-20.78%	-42.82%	39.11%	39.33%	-23.25%	154.21%	-33.03%	-6.54%	-25.10%	51.00%
EBIT Q/Q Growth	34.35%	-24.75%	-51.81%	56.70%	50.69%	-44.84%	244.61%	-40.11%	-9.32%	-39.83%	98.34%
NOPAT Q/Q Growth	6.32%	-8.09%	1,581.80%	-94.86%	43.40%	-28.23%	141.00%	-34.10%	-22.12%	-42.62%	133.77%
Net Income Q/Q Growth	12.52%	-10.49%	341.33%	-79.98%	34.72%	-54.13%	257.70%	-36.14%	-19.66%	-57.60%	243.12%
EPS Q/Q Growth	8.14%	-8.60%	340.00%	-80.21%	36.49%	-55.45%	262.22%	-36.20%	-21.15%	-71.95%	391.30%
Operating Cash Flow Q/Q Growth	-90.86%	1,171.75%	-87.95%	-169.35%	1,162.47%	-126.86%	515.14%	-38.44%	-173.65%	373.08%	-53.12%
Free Cash Flow Firm Q/Q Growth	20.93%	182.96%	733.08%	-123.54%	92.36%	-8,719.29%	26.72%	4.12%	-29.42%	109.85%	0.88%
Invested Capital Q/Q Growth	15.09%	-22.13%	55.14%	7.65%	-11.67%	178.62%	-2.20%	-1.60%	9.74%	-9.65%	0.36%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	26.70%	25.72%	25.82%	25.81%	29.21%	27.36%	31.16%	29.44%	28.13%	26.72%	29.75%
EBITDA Margin	11.87%	10.14%	4.78%	7.68%	10.84%	5.92%	13.10%	9.31%	8.83%	6.68%	9.80%
Operating Margin	10.13%	8.14%	9.80%	5.32%	9.28%	3.35%	11.02%	6.76%	5.86%	3.72%	7.31%
EBIT Margin	10.34%	8.39%	3.34%	6.00%	9.16%	3.59%	10.77%	7.00%	6.44%	3.91%	7.54%
Profit (Net Income) Margin	5.61%	5.41%	19.72%	4.62%	6.31%	2.06%	6.41%	4.44%	3.62%	1.55%	5.17%
Tax Burden Percent	58.41%	72.06%	829.92%	92.10%	76.70%	108.47%	69.20%	80.59%	73.50%	67.08%	77.63%
Interest Burden Percent	92.87%	89.53%	71.19%	83.74%	89.89%	52.86%	86.01%	78.75%	76.50%	59.06%	88.29%
Effective Tax Rate	41.59%	27.94%	-729.92%	7.90%	23.30%	-8.47%	30.80%	19.41%	26.50%	32.92%	22.37%
Return on Invested Capital (ROIC)	54.47%	51.82%	534.60%	32.86%	47.56%	14.45%	30.39%	23.55%	19.52%	8.26%	18.56%
ROIC Less NNEP Spread (ROIC-NNEP)	55.44%	52.98%	748.46%	33.57%	49.30%	-51.08%	135.37%	55.21%	34.54%	4.92%	16.12%
Return on Net Nonoperating Assets (RNNOA)	-22.41%	-23.47%	-258.33%	-12.91%	-20.99%	-1.53%	-1.97%	-1.98%	-1.67%	1.44%	3.30%
Return on Equity (ROE)	32.06%	28.35%	276.27%	19.95%	26.57%	12.91%	28.42%	21.57%	17.85%	9.69%	21.86%
Cash Return on Invested Capital (CROIC)	-2.58%	52.71%	68.88%	47.63%	78.74%	-68.63%	-65.55%	-56.03%	-74.76%	21.41%	16.90%
Operating Return on Assets (OROA)	18.48%	13.60%	5.36%	9.45%	14.27%	5.01%	15.73%	11.32%	11.37%	6.17%	11.41%
Return on Assets (ROA)	10.02%	8.78%	31.67%	7.29%	9.84%	2.87%	9.36%	7.18%	6.39%	2.44%	7.82%
Return on Common Equity (ROCE)	31.28%	27.57%	268.90%	19.42%	25.90%	12.60%	27.67%	21.01%	17.42%	9.46%	21.27%
Return on Equity Simple (ROE_SIMPLE)	17.90%	20.35%	0.00%	33.52%	31.97%	29.30%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	2.98	2.74	46	2.37	3.40	2.44	5.88	3.88	3.02	1.73	4.05
NOPAT Margin	5.92%	5.86%	81.35%	4.90%	7.12%	3.63%	7.62%	5.45%	4.31%	2.50%	5.67%
Net Nonoperating Expense Percent (NNEP)	-0.97%	-1.16%	-213.85%	-0.71%	-1.74%	65.53%	-104.98%	-31.66%	-15.01%	3.34%	2.44%
Return On Investment Capital (ROIC_SIMPLE)	6.03%	5.62%	77.47%	-	5.52%	2.41%	5.64%	3.65%	2.80%	1.82%	4.18%
Cost of Revenue to Revenue	73.30%	74.28%	74.18%	74.19%	70.79%	72.64%	68.84%	70.56%	71.87%	73.28%	70.25%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	16.57%	17.58%	16.02%	20.48%	19.93%	24.01%	20.14%	22.67%	22.27%	23.00%	22.45%
Earnings before Interest and Taxes (EBIT)	5.22	3.93	1.89	2.90	4.37	2.41	8.31	4.98	4.51	2.72	5.39
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	5.99	4.74	2.71	3.72	5.18	3.98	10	6.62	6.19	4.64	7.00
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.26	1.85	1.87	2.82	1.54	3.04	1.40	2.35	1.72	1.60	1.42
Price to Tangible Book Value (P/TBV)	1.26	1.85	1.87	2.82	1.54	6.49	2.65	4.24	2.97	2.73	2.31
Price to Revenue (P/Rev)	0.25	0.41	0.50	0.78	0.46	0.84	0.38	0.60	0.42	0.39	0.38
Price to Earnings (P/E)	7.64	9.35	5.47	8.55	4.86	10.50	7.93	12.79	10.21	10.23	11.03
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	13.08%	10.69%	18.27%	11.69%	20.58%	9.52%	12.62%	7.82%	9.80%	9.78%	9.07%
Enterprise Value to Invested Capital (EV/IC)	1.39	2.73	2.42	3.82	1.99	2.39	1.30	2.05	1.53	1.50	1.37
Enterprise Value to Revenue (EV/Rev)	0.18	0.29	0.40	0.68	0.32	0.97	0.47	0.67	0.50	0.44	0.41
Enterprise Value to EBITDA (EV/EBITDA)	2.22	3.12	4.52	8.05	3.90	13.66	4.92	6.80	5.36	4.63	4.77
Enterprise Value to EBIT (EV/EBIT)	2.67	3.71	5.46	9.91	4.87	18.39	6.28	8.77	7.12	6.22	6.63
Enterprise Value to NOPAT (EV/NOPAT)	4.66	6.03	3.07	5.24	2.30	7.24	8.12	11.46	9.62	8.78	9.16
Enterprise Value to Operating Cash Flow (EV/OCF)	6.77	3.26	4.17	13.03	3.48	32.65	7.64	8.24	16.62	5.65	6.26
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	4.94	3.82	9.61	2.71	0.00	0.00	0.00	0.00	6.85	8.01
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.14	0.08	0.06	0.07	0.02	0.63	0.57	0.54	0.50	0.31	0.26
Long-Term Debt to Equity	0.01	0.01	0.00	0.00	0.00	0.57	0.51	0.49	0.45	0.23	0.20
Financial Leverage	-0.40	-0.44	-0.35	-0.38	-0.43	0.03	-0.01	-0.04	-0.05	0.29	0.20
Leverage Ratio	3.07	3.04	2.68	2.62	2.46	2.94	2.69	2.58	2.44	2.71	2.61
Compound Leverage Factor	2.85	2.72	1.91	2.19	2.21	1.55	2.31	2.03	1.87	1.60	2.30
Debt to Total Capital	12.34%	7.03%	5.60%	6.27%	1.56%	38.72%	36.44%	35.10%	33.41%	23.89%	20.70%
Short-Term Debt to Total Capital	11.82%	6.53%	5.20%	5.91%	1.31%	4.08%	3.73%	3.20%	3.73%	6.75%	5.13%
Long-Term Debt to Total Capital	0.52%	0.51%	0.39%	0.36%	0.25%	34.64%	32.71%	31.90%	29.68%	17.13%	15.57%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	2.64%	2.58%	2.43%	2.43%	2.16%	1.30%	1.72%	1.69%	1.73%	1.94%	2.16%
Common Equity to Total Capital	85.02%	90.38%	91.97%	91.30%	96.28%	59.98%	61.84%	63.21%	64.86%	74.17%	77.14%
Debt to EBITDA	0.35	0.18	0.18	0.22	0.06	2.52	1.65	1.44	1.34	0.83	0.82
Net Debt to EBITDA	-0.89	-1.25	-1.25	-1.24	-1.76	1.73	0.91	0.65	0.83	0.45	0.35
Long-Term Debt to EBITDA	0.01	0.01	0.01	0.01	0.01	2.25	1.48	1.31	1.19	0.59	0.62
Debt to NOPAT	0.74	0.35	0.13	0.15	0.03	1.34	2.73	2.42	2.40	1.57	1.57
Net Debt to NOPAT	-1.88	-2.41	-0.85	-0.81	-1.04	0.92	1.50	1.09	1.49	0.85	0.66
Long-Term Debt to NOPAT	0.03	0.03	0.01	0.01	0.01	1.19	2.45	2.20	2.13	1.12	1.18
Altman Z-Score	3.22	3.22	3.33	3.91	3.42	2.85	2.62	3.07	3.11	3.24	3.23
Noncontrolling Interest Sharing Ratio	2.44%	2.75%	2.67%	2.65%	2.53%	2.40%	2.64%	2.60%	2.41%	2.36%	2.71%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.35	2.28	2.37	2.53	2.64	2.16	2.20	2.32	2.48	2.12	2.18
Quick Ratio	1.45	1.48	1.68	1.85	1.86	1.33	1.44	1.51	1.56	1.28	1.42
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-5.92	4.91	41	-9.64	-0.74	-65	-48	-46	-59	5.82	5.87
Operating Cash Flow to CapEx	59.05%	2,000.00%	116.96%	-285.61%	1,235.14%	-328.88%	1,823.06%	751.10%	-271.66%	1,743.56%	588.36%
Free Cash Flow to Firm to Interest Expense	-15.92	11.95	75.10	-20.41	-1.67	-57.11	-40.91	-43.12	-55.65	5.23	9.30
Operating Cash Flow to Interest Expense	2.01	23.11	2.10	-1.68	19.09	-1.99	8.09	5.47	-4.02	10.47	8.65
Operating Cash Flow Less CapEx to Interest Expense	-1.39	21.96	0.30	-2.27	17.54	-2.60	7.64	4.74	-5.50	9.87	7.18
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.79	1.62	1.61	1.58	1.56	1.40	1.46	1.62	1.76	1.58	1.51
Accounts Receivable Turnover	5.12	4.72	4.47	4.70	4.73	4.47	4.48	5.24	5.66	5.16	4.66
Inventory Turnover	7.32	7.09	7.13	7.23	7.27	6.01	6.41	6.86	7.48	6.34	6.36
Fixed Asset Turnover	13.26	12.55	11.97	11.74	11.47	10.64	11.78	13.19	14.22	12.39	12.38
Accounts Payable Turnover	8.01	6.97	6.47	7.00	7.21	7.36	6.82	7.92	9.18	8.49	8.15
Days Sales Outstanding (DSO)	71.34	77.25	81.64	77.58	77.23	81.72	81.54	69.65	64.50	70.75	78.39
Days Inventory Outstanding (DIO)	49.85	51.51	51.21	50.49	50.22	60.70	56.92	53.22	48.82	57.53	57.39
Days Payable Outstanding (DPO)	45.59	52.39	56.37	52.13	50.60	49.57	53.49	46.09	39.77	42.99	44.81
Cash Conversion Cycle (CCC)	75.60	76.37	76.47	75.94	76.85	92.85	84.98	76.78	73.55	85.29	90.97
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	28	22	34	36	32	89	87	86	94	85	85
Invested Capital Turnover	9.21	8.84	6.57	6.71	6.68	3.98	3.99	4.32	4.53	3.31	3.27
Increase / (Decrease) in Invested Capital	8.91	-2.17	5.20	12	4.14	67	53	49	62	-4.09	-1.82
Enterprise Value (EV)	39	59	81	138	64	213	113	176	144	128	117
Market Capitalization	53	82	103	158	91	185	90	157	120	113	106
Book Value per Share	$14.50	$15.19	$19.05	$19.73	$20.66	$21.17	$22.58	$23.58	$24.38	$24.66	$26.07
Tangible Book Value per Share	$14.50	$15.19	$19.05	$19.73	$20.66	$9.90	$11.96	$13.06	$14.06	$14.48	$16.03
Total Capital	50	49	60	61	62	101	104	106	108	95	97
Total Debt	6.11	3.43	3.33	3.85	0.96	39	38	37	36	23	20
Total Long-Term Debt	0.26	0.25	0.24	0.22	0.16	35	34	34	32	16	15
Net Debt	-16	-24	-23	-21	-29	27	21	17	22	12	8.44
Capital Expenditures (CapEx)	1.27	0.48	0.98	0.28	0.68	0.69	0.52	0.77	1.57	0.67	0.93
Debt-free, Cash-free Net Working Capital (DFCFNWC)	36	30	33	34	31	50	51	50	58	51	50
Debt-free Net Working Capital (DFNWC)	58	57	59	60	61	63	69	70	72	61	62
Net Working Capital (NWC)	52	54	56	56	60	58	65	67	68	55	57
Net Nonoperating Expense (NNE)	0.15	0.21	35	0.13	0.39	1.06	0.93	0.72	0.48	0.66	0.36
Net Nonoperating Obligations (NNO)	-16	-24	-23	-21	-29	27	21	17	22	12	8.44
Total Depreciation and Amortization (D&A)	0.77	0.82	0.82	0.82	0.81	1.56	1.79	1.64	1.67	1.92	1.61
Debt-free, Cash-free Net Working Capital to Revenue	16.87%	14.97%	16.29%	17.03%	15.58%	22.83%	21.36%	18.85%	20.37%	17.68%	17.87%
Debt-free Net Working Capital to Revenue	26.97%	28.45%	29.02%	29.48%	30.44%	28.44%	28.50%	26.62%	25.17%	21.28%	21.99%
Net Working Capital to Revenue	24.24%	26.87%	27.50%	27.69%	30.04%	26.56%	26.89%	25.33%	23.76%	19.04%	20.23%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.94	$0.87	$3.83	$0.77	$1.05	$0.47	$1.69	$1.08	$0.85	$0.24	$1.19
Adjusted Weighted Average Basic Shares Outstanding	2.90M	2.89M	2.88M	2.85M	2.87M	2.87M	2.86M	2.85M	2.87M	2.87M	2.86M
Adjusted Diluted Earnings per Share	$0.93	$0.85	$3.74	$0.74	$1.01	$0.45	$1.63	$1.04	$0.82	$0.23	$1.13
Adjusted Weighted Average Diluted Shares Outstanding	2.93M	2.97M	2.94M	2.97M	2.97M	3.00M	2.98M	2.96M	2.99M	2.98M	2.98M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	2.90M	2.88M	2.84M	2.87M	2.87M	2.85M	2.84M	2.87M	2.87M	2.87M	2.87M
Normalized Net Operating Profit after Tax (NOPAT)	2.98	2.74	3.89	2.37	3.40	1.58	5.88	3.88	3.02	1.73	4.05
Normalized NOPAT Margin	5.92%	5.86%	6.86%	4.90%	7.12%	2.34%	7.62%	5.45%	4.31%	2.50%	5.67%
Pre Tax Income Margin	9.61%	7.51%	2.38%	5.02%	8.23%	1.90%	9.27%	5.51%	4.93%	2.31%	6.66%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	14.02	9.55	3.47	6.15	9.89	2.12	7.15	4.71	4.25	2.44	8.54
NOPAT to Interest Expense	8.02	6.67	84.64	5.02	7.69	2.15	5.06	3.66	2.85	1.56	6.42
EBIT Less CapEx to Interest Expense	10.62	8.40	1.68	5.56	8.35	1.52	6.70	3.98	2.77	1.84	7.07
NOPAT Less CapEx to Interest Expense	4.62	5.52	82.84	4.44	6.15	1.54	4.61	2.94	1.37	0.96	4.95
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	2.25%	0.00%	0.83%	3.75%	3.24%
Augmented Payout Ratio	0.00%	8.82%	10.48%	0.00%	0.00%	6.78%	16.03%	0.00%	0.83%	3.75%	3.24%

Financials Breakdown Chart

Kewaunee Scientific Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Kewaunee Scientific's fiscal year ends in April. Their fiscal year 2026 ended on April 30, 2026.

Kewaunee Scientific's net income appears to be on an upward trend, with a most recent value of $10.47 million in 2026, rising from $3.88 million in 2016. The previous period was $11.58 million in 2025. See where experts think Kewaunee Scientific is headed by visiting Kewaunee Scientific's forecast page.

Kewaunee Scientific's total operating income in 2026 was $16.72 million, based on the following breakdown:

Total Gross Profit: $80.44 million
Total Operating Expenses: $63.73 million

Over the last 10 years, Kewaunee Scientific's total revenue changed from $128.63 million in 2016 to $282.00 million in 2026, a change of 119.2%.

Kewaunee Scientific's total liabilities were at $101.50 million at the end of 2026, a 21.0% decrease from 2025, and a 199.8% increase since 2016.

In the past 10 years, Kewaunee Scientific's cash and equivalents has ranged from $4.37 million in 2020 to $23.27 million in 2024, and is currently $9.95 million as of their latest financial filing in 2026.

Over the last 10 years, Kewaunee Scientific's book value per share changed from 14.25 in 2016 to 26.07 in 2026, a change of 83.0%.

Related Companies

Financial statements for NASDAQ:KEQU last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kewaunee Scientific (KEQU) Financials

Financials Breakdown Chart

Kewaunee Scientific Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kewaunee Scientific (KEQU) Financials

Annual Income Statements for Kewaunee Scientific

Quarterly Income Statements for Kewaunee Scientific

Annual Cash Flow Statements for Kewaunee Scientific

Quarterly Cash Flow Statements for Kewaunee Scientific

Annual Balance Sheets for Kewaunee Scientific

Quarterly Balance Sheets for Kewaunee Scientific

Annual Metrics And Ratios for Kewaunee Scientific

Quarterly Metrics And Ratios for Kewaunee Scientific

Financials Breakdown Chart

Kewaunee Scientific Financials - Frequently Asked Questions

When does Kewaunee Scientific's financial year end?

How has Kewaunee Scientific's net income changed over the last 10 years?

What is Kewaunee Scientific's operating income?

How has Kewaunee Scientific's revenue changed over the last 10 years?

How much debt does Kewaunee Scientific have?

How much cash does Kewaunee Scientific have?

How has Kewaunee Scientific's book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools